WallStreetZenWallStreetZen

NASDAQ: CHRS
Coherus Biosciences Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CHRS past revenue growth

How has CHRS's revenue growth performed historically?
Company
21.89%
Industry
143.99%
Market
17.8%
CHRS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CHRS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CHRS's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CHRS earnings and revenue history

Current Revenue
$257.2M
Current Earnings
-$237.9M
Current Profit Margin
-92.5%

CHRS Return on Equity

Current Company
N/A
Current Industry
-63.5%
Current Market
188%

Be the first to know when CHRS announces earnings.

CHRS Return on Assets

Current Company
-45.6%
Current Industry
2.9%
CHRS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CHRS Return on Capital Employed

Current Company
-66.39%
Current Industry
19.5%
CHRS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CHRS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CHRS$257.24M-$191.46M-$237.89M-7.81%N/A
ATNM$81.00k-$45.63M-$46.45M-95.46%N/A
STRO$153.73M-$66.98M-$106.79M+31.96%N/A
CADL$0.00-$34.14M-$37.94MN/AN/A
TSVT$100.39M-$207.29M-$217.57M+12.96%N/A
View Top Biotech Stocks

CHRS earnings dates

Next earnings date
Jun 6, 2024

Coherus Biosciences Earnings & Revenue FAQ

What were CHRS's earnings last quarter?

On Invalid Date, Coherus Biosciences (NASDAQ: CHRS) reported Q4 2023 earnings per share (EPS) of -$0.74, up 2.63% year over year. Total Coherus Biosciences earnings for the quarter were -$79.65 million. In the same quarter last year, Coherus Biosciences's earnings per share (EPS) was -$0.76.

If you're new to stock investing, here's how to buy Coherus Biosciences stock.

What was CHRS's earnings growth in the past year?

As of Q2 2024, Coherus Biosciences's earnings has grown year over year. Coherus Biosciences's earnings in the past year totalled -$237.89 million.

What is CHRS's earnings date?

Coherus Biosciences's earnings date is Invalid Date. Add CHRS to your watchlist to be reminded of CHRS's next earnings announcement.

What was CHRS's revenue last quarter?

On Invalid Date, Coherus Biosciences (NASDAQ: CHRS) reported Q4 2023 revenue of $91.52 million up 101.81% year over year. In the same quarter last year, Coherus Biosciences's revenue was $45.35 million.

What was CHRS's revenue growth in the past year?

As of Q2 2024, Coherus Biosciences's revenue has grown 21.89% year over year. This is 122.09 percentage points lower than the US Biotechnology industry revenue growth rate of 143.99%. Coherus Biosciences's revenue in the past year totalled $257.24 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.